The company's main focus is on the development and commercialization of Breceptin, a unique oncolytic drug that induces cancer cell apoptosis by targeting specific receptors on the surface of tumor cells. Breceptin shows promise in treating a wide range of solid tumors, providing a potential breakthrough in cancer treatment. Additionally, ApopLogic Pharmaceuticals is also working on the development and commercialization of B201-acetate and AP-300, further expanding its portfolio of therapeutic products.